KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) Equity Average (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Equity Average for 17 consecutive years, with $490.3 million as the latest value for Q1 2026.

  • For Q1 2026, Equity Average fell 7.85% year-over-year to $490.3 million; the TTM value through Mar 2026 reached $490.3 million, down 7.85%, while the annual FY2025 figure was $538.7 million, 10.5% up from the prior year.
  • Equity Average hit $490.3 million in Q1 2026 for Ionis Pharmaceuticals, down from $553.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $740.7 million in Q1 2022 and bottomed at $280.1 million in Q2 2024.
  • Average Equity Average over 5 years is $516.2 million, with a median of $532.0 million recorded in 2025.
  • Year-over-year, Equity Average crashed 39.85% in 2023 and then soared 97.68% in 2025.
  • Ionis Pharmaceuticals' Equity Average stood at $583.6 million in 2022, then plummeted by 39.85% to $351.1 million in 2023, then skyrocketed by 78.14% to $625.4 million in 2024, then fell by 11.49% to $553.5 million in 2025, then decreased by 11.43% to $490.3 million in 2026.
  • According to Business Quant data, Equity Average over the past three periods came in at $490.3 million, $553.5 million, and $624.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.